Rely+On Virkon from LANXESS: highly effective against yeast Candida auris
- Efficient prevention of drug resistant yeast
- Disinfection as key measure to prevent infections
- Effective even at short contact times
The broad spectrum disinfectant Rely+On Virkon from specialty chemicals company LANXESS has proven effective against the yeast Candida auris. Thus, it can be used as disinfectant in healthcare and institutional facilities where an infection with the drug resistant yeast is either demonstrated, indeed suspected or should be prevented from the start. The disinfectant is effective at short contact times (0.75% in 5 minutes according to EN 1650) and enables hard surface disinfection and decontamination. In addition, it is also suitable for laboratory related applications.
Anneliese Bischof, Head of the Business Line CARE at LANXESS’ Material Protection Products business unit, says: “Practicing good hygiene must always be a part of our everyday routines, but the selection of a disinfectant proven to kill key pathogens is crucial.”
With cases of drug resistant pathogens continuing to cause significant concerns in healthcare facilities around the world, government health departments are providing advice and guidance on how to better prevent their transmission with hygiene and disinfection remaining of the utmost importance. The US CDC reports that 90 percent of Candida auris isolates are resistant to at least one antifungal medication, and 30 percent of them are resistant to at least two antifungal medications.
“Therefore, utilizing Rely+On Virkon as a surface disinfectant for the purposes of infection control can help to disinfect areas where a high risk of Candida auris transmission exists, and consequently reduce the risk of infection to patients, and both medical and laboratory staff,” Bischof concludes.
Further information can be found at www.relyondisinfection.com.
Forward-Looking Statements
This company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors, nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.
Information for editors:
All global LANXESS news releases and their accompanying photos can be found at http://press.lanxess.com.
Recent photos of the Board of Management and other LANXESS image material are available at http://photos.lanxess.com.
